➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Express Scripts
Merck
McKinsey
Colorcon

Last Updated: April 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BAVENCIO

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for BAVENCIO

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03147287 Palbociclib After CDK and Endocrine Therapy (PACE) Not yet recruiting Pfizer Phase 2 2017-06-30 This research study is studying three combinations of drugs as treatments for breast cancer. The drugs involved in this study are: - Fulvestrant - Fulvestrant with Palbociclib - Fulvestrant with Palbociclib and Avelumab
NCT03147287 Palbociclib After CDK and Endocrine Therapy (PACE) Not yet recruiting Dana-Farber Cancer Institute Phase 2 2017-06-30 This research study is studying three combinations of drugs as treatments for breast cancer. The drugs involved in this study are: - Fulvestrant - Fulvestrant with Palbociclib - Fulvestrant with Palbociclib and Avelumab
NCT03147404 Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic (GEP) Neuroendocrine Carcinoma (NEC, WHO Grade 3) as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes Not yet recruiting Samsung Medical Center Phase 2 2017-07-01 Phase II study of avelumab in metastatic gastronetro-pancreatic (GEP) neuroendocrine carcinoma (NEC, WHO grade 3) as second-line treatment after failing to etoposide+cisplatin: integration of genomic analysis to identify predictive molecular subtypes
NCT03267836 Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma Not yet recruiting Pfizer Phase 1 2017-12-01 Currently, there is no standard radiation therapy (RT) dosing regimen for re-irradiation of recurrent brain tumors, and the optimal RT fractionation to combine with immunotherapy has not been definitively established. Hypofractionated RT in 3-5 fractions is currently favored as the preferred fractionation to combine with immunotherapy in most clinical trials. Multiple clinical studies have demonstrated that the combination of extra-cranial or intra-cranial RT with PD-1 inhibitor is well-tolerated and have not shown any significant overlapping toxicity. Given the primary purpose of re-irradiation in the proposed study is to stimulate immune response rather than to ablate the recurrent meningioma and that many recurrent meningiomas may be larger than 3.5 cm, the present study will use a lower dose of hypofractionated RT of 4 CGE (cobalt gray equivalent) x 5 fractions (EQD2 ~ 28 Gy, assuming α/β of 3 for brain tissue and RBE of 1.1 for proton therapy), which should provide optimal balance of feasibility/generalizability and potential synergy with PD-1 blockade. Although preclinical data suggest the combination of ionizing radiation and PD-1 blockade increases tumor immunogenicity, this has not been confirmed in patients. This study is designed to provide proof of concept to demonstrate on-target effect of the combination to increase immunogenicity and to evaluate preliminary clinical efficacy.
NCT03267836 Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma Not yet recruiting Washington University School of Medicine Phase 1 2017-12-01 Currently, there is no standard radiation therapy (RT) dosing regimen for re-irradiation of recurrent brain tumors, and the optimal RT fractionation to combine with immunotherapy has not been definitively established. Hypofractionated RT in 3-5 fractions is currently favored as the preferred fractionation to combine with immunotherapy in most clinical trials. Multiple clinical studies have demonstrated that the combination of extra-cranial or intra-cranial RT with PD-1 inhibitor is well-tolerated and have not shown any significant overlapping toxicity. Given the primary purpose of re-irradiation in the proposed study is to stimulate immune response rather than to ablate the recurrent meningioma and that many recurrent meningiomas may be larger than 3.5 cm, the present study will use a lower dose of hypofractionated RT of 4 CGE (cobalt gray equivalent) x 5 fractions (EQD2 ~ 28 Gy, assuming α/β of 3 for brain tissue and RBE of 1.1 for proton therapy), which should provide optimal balance of feasibility/generalizability and potential synergy with PD-1 blockade. Although preclinical data suggest the combination of ionizing radiation and PD-1 blockade increases tumor immunogenicity, this has not been confirmed in patients. This study is designed to provide proof of concept to demonstrate on-target effect of the combination to increase immunogenicity and to evaluate preliminary clinical efficacy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for BAVENCIO

Condition Name

Condition Name for BAVENCIO
Intervention Trials
Breast Cancer 4
Metastatic Breast Cancer 2
Neoplasms 2
Advanced Malignant Solid Neoplasm 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for BAVENCIO
Intervention Trials
Carcinoma 16
Breast Neoplasms 7
Neoplasms 6
Carcinoma, Squamous Cell 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for BAVENCIO

Trials by Country

Trials by Country for BAVENCIO
Location Trials
United States 40
Australia 2
Korea, Republic of 2
United Kingdom 2
Belgium 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for BAVENCIO
Location Trials
Texas 5
California 4
Missouri 3
Minnesota 3
Maryland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for BAVENCIO

Clinical Trial Phase

Clinical Trial Phase for BAVENCIO
Clinical Trial Phase Trials
Phase 3 2
Phase 2 25
Phase 1/Phase 2 8
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for BAVENCIO
Clinical Trial Phase Trials
Not yet recruiting 33
Recruiting 12
Suspended 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for BAVENCIO

Sponsor Name

Sponsor Name for BAVENCIO
Sponsor Trials
Pfizer 15
National Cancer Institute (NCI) 13
M.D. Anderson Cancer Center 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for BAVENCIO
Sponsor Trials
Other 46
Industry 31
NIH 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Harvard Business School
Express Scripts
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.